Defining the Outcome Markers and Therapeutic Role for Omalizumab in Treatment of Allergic Bronchopulmonary Aspergillosis

J Allergy Clin Immunol Pract. 2023 Mar;11(3):906-907. doi: 10.1016/j.jaip.2023.01.013. Epub 2023 Jan 24.

Author

Paul A Greenberger¹

Affiliation

¹ Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: p-greenberger@northwestern.edu.

PMID: 36702248
DOI: 10.1016/j.jaip.2023.01.013

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Allergic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Aspergillosis, Allergic Bronchopulmonary* / drug therapy
Humans
Omalizumab / therapeutic use
Treatment Outcome

Substances

Omalizumab
Anti-Allergic Agents
Antibodies, Monoclonal, Humanized